BROOKFIELD, Wis., June 11, 2021 (Newswire.com) - A controlled, randomized trial sought to compare outcomes between in-home biofeedback therapy and office biofeedback therapy for the treatment of Fecal Incontinence. The study evaluated the performance of InControl's biofeedback device to in-office therapy, and delivered findings to suggest both are equally effective paths to treating Fecal Incontinence.
The study, which involved men and women between the ages of 35 and 84 years old, sought to measure outcomes as home biofeedback is a particularly attractive treatment modality for FI patients. Office biofeedback therapy required patients to schedule and attend office visits, undergoing treatment with a professional at least once per week, while home biofeedback equipped participants with a device they were able to use daily at home. The study found that both in-office and at-home modalities offered similar increases in sustained squeeze pressure and reduction in fecal incontinence episodes. The authors note the study provides doctors and patients with meaningful treatment alternatives where in-office visits are not desired or possible, such as during a global pandemic.
Xiang X, Sharma A, Patcharatrakul T, et al. Randomized controlled trial of home biofeedback therapy versus office biofeedback therapy for fecal incontinence. Neurogastroenterology & Motility. 2021;00:e14168. https://doi.org/10.1111/nmo.14168
Source: InControl Medical